Thursday, Feb 22 2018 | Time 15:43 Hrs(IST)
image
image image
  • Playing for India is my ultimate dream: Abhishek Ambekar
  • Vijay Hazare Trophy: Andhra storms into semis after thrashing Delhi
  • BJD and BJP indulges in mudslinging as campaign comes to an end for Bijepur Assembly by poll
  • Panthers Party protests in Jammu against settling of Rohingyas
  • Cauvery issue unites TN, All party meet held to discuss SC verdict
  • Ramco Systems partners with ITOrizon to offer Next-Gen integrate supply chain
  • Reference rate fixed at 65 0458 against USD
  • Reliance Infrastructure Limited bags Rs 3,647 Crore EPC Contract for Prestigious Uppur Thermal Power Project
  • DSP BlackRock Mutual Fund launches DSP BlackRock Liquid ETF
  • BSE signs an MOU with Soybean Processors Association of India (SOPA)
  • Volvo launches new V60 versatile family estate
  • Sugar rates steady in Kolhapur market today
  • Three-judge judgement on land acquisition to be heard by larger bench: SC
  • India, Canada decide to strengthen ties in trade, cyber security
Science & Technology » Science  Share

Vardhan launches National Biopharma Mission

Vardhan launches National Biopharma Mission

New Delhi, Jun 30 (UNI) The first ever Industry-Academia mission to accelerate biopharmaceutical development in the country was formally launched today by Union Science and Technology Minister Harsh Vardhan here.
Biopharma mission can bring major change in the healthcare technologies, he said.
'It is time for India to capitalise now on our unique strengths and overcome any hurdles to ensure success in the bio-pharmaceutical market,' Dr Vardhan said.
The first ever Industry-Academia mission to accelerate biopharmaceutical development in India has been approved by the Government.
The program named Innovate in India (i3) will witness an investment of USD 250 million with USD 125 million as a loan from World Bank and aspires to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the sector.
This Mission of the Department of Biotechnology (DBT), Ministry of Science & Technology will be implemented by Biotechnology Industry Research Assistance Council (BIRAC) - a Public Sector Undertaking of DBT.
The programme will specifically focus on the development of new vaccines, bio-therapeutics, diagnostics and medical devices to better address the rising burden of diseases in the country.
It will also bring isolated centres of excellence together, enhance regional capabilities and strengthen the current bio-clusters network in terms of capacities as well as quantity and quality of output.
The programme will help deliver 6-10 new products in the next five years, create several dedicated facilities for next-generation skills, and hundreds of jobs in the process.
It will provide young entrepreneurs the confidence as well as the systemic support to pursue their aspirations in biotechnological innovation, and transform India into a global hub for cutting-edge biotechnology research and development.
As a flagship program of the Government in collaboration with World Bank, it promises to boost the growth curve for domestic biopharma in India by accelerating the translation of research concepts into viable products, supporting clinical validation, enabling sustainable networks for collaboration between industry and academia, and supporting entrepreneurial ecosystem amongst many others.
Currently India has only 2.
8 per cent share in the global biopharmaceutical market, the program would elevate this to 5 per cent resulting in an additional business opportunity of 16 Billion USD.
The oversight to the program would be provided by the Inter-Ministerial Steering Committee comprising of members from various Ministries; and would be supported by Program Technical Advisory Group comprising of global and national leaders from industry and academia.
The program thereby stands unique in its approach with involvement of global experts, industry leaders and World Bank in driving it and ensuring world class biomedical products are born out of the initiative.
This Mission is anticipated to be a game changer for the Indian Biopharmaceutical industry.
UNI NY SB 2049

image